As a new-type foreign trade service provider driven by both technology commercialization and foreign trade, HiSiaddi has established a service system summarized as “1+2+3+4=1” and can supply dibenzyl ether sourced from multiple well-known original manufacturers. With over a decade of market experience and technological cooperation with manufacturers, HiSiaddi possesses extensive expertise addressing product compliance challenges. Below is a case detailing HiSiaddi’s resolution of dibenzyl ether compliance issues.
Contact HiSiaddi customer service for more inquiries regarding dibenzyl ether product compliance.
This case follows the cooperative client HEC Finechem GmbH of Germany outlined in Case 3, a listed Bavarian pharmaceutical enterprise specializing in anti-infective API and peptide new drug R&D & manufacturing, with full product distribution covering all 27 EU member states and North American prescription drug markets. Dibenzyl ether is deployed in the hydroxyl protection step of pharmaceutical synthesis under a 90-ton annual framework procurement contract for pharmaceutical-grade dibenzyl ether, subject to multiple entry standards including the European Pharmacopoeia (EP), full REACH registration, CLP labeling regulations, EU pharmaceutical GMP supply chain control and mandatory German customs dangerous goods inspection.
After the client finalized three product grades (Jiangsu Hualun HL-998EP, HL-995 and Zhejiang Lianhua LH-PH), the first 45-ton batch was fully stocked ready for shipment, yet four interlocking compliance bottlenecks emerged immediately: original manufacturer supporting documentation failed to comply with latest EU regulations, outdated SDS versions could not satisfy German customs clearance requirements, misclassification of dibenzyl ether dangerous goods and mismatched HS codes, and absence of EU supply chain compliance filings for pharmaceutical-grade raw materials. A pre-inspection alert issued by German import customs notified the client that incomplete documentation would result in full-container detention and potential return shipment, incurring high port detention fees and order breach damages. The client fully entrusted HiSiaddi to coordinate full-process compliance rectification and compile a complete set of statutory documentation.
Dibenzyl ether exports exceeding 1 ton annually to the EU mandate complete substance main registration and an EU-based Only Representative (OR) under REACH regulation. Domestic manufacturers only conduct domestic production holding outdated pre-registration certificates without formal main registration numbers or Letter of Authorization (LOA) documents for annual tonnage allocation required by the European Union. New German customs regulations mandate submission of registration credentials alongside shipments; unregistered goods are denied entry into EU territory. Independent registration in Germany by the client would exceed a 3-month cycle, directly delaying production scheduling. Additionally, manufacturers failed to complete latest full SVHC 253-substance screening reports required under ECHA 2025 regulations, with only simplified self-inspection reports unavailable for acceptance by EU pharmaceutical regulatory authorities.
Original SDS issued by manufacturers were translated versions of outdated Chinese national standard documents containing only 16 basic sections, lacking CLP hazard classification labeling, ecotoxicological data, pharmaceutical exposure limits and German local emergency response clauses; only English versions were provided without German translations. German chemical regulations mandate native German SDS for warehouse admission. Outdated documentation fails both domestic export commodity inspection and German pharmaceutical enterprise QA warehouse audits. Domestic manufacturer quality inspection departments lack capabilities to compile EU-compliant documentation within short timeframes.
Dibenzyl ether carries UN1993 classification with Class III dangerous goods packaging standards. Domestic manufacturers default to general industrial solvent HS codes for customs declaration, misclassifying the product as ordinary chemicals without adopting specialized subdivided HS codes for pharmaceutical fine ethers. Incorrect coding triggers mandatory dangerous goods inspection failure by domestic customs; additionally, 200L drums lack German-English bilingual CLP hazard pictogram labels required for dual China-EU packaging compliance, with freight forwarders refusing container booking and shipment loading.
The client’s German EMA drug regulatory filing for API production requires EP Pharmacopoeia-format English CoAs, factory GMP production statements and raw material traceability quality control documentation. Domestic manufacturer CoAs adopt Chinese national standard formatting with test items and limit thresholds aligned to national standards rather than the European Pharmacopoeia, making them unrecordable within the client’s pharmaceutical quality system. Even upon successful port arrival, goods would be prohibited from warehouse entry and production use.
HiSiaddi assembled a dedicated cross-functional team consisting of chemical compliance specialists, REACH certification consultants, customs brokers and pharmaceutical quality control specialists to complete full compliance documentation within 12 working days across four core modules, coordinating manufacturers to revise product labels and test items concurrently.
1. HiSiaddi engaged an EU-certified OR (Irish local compliance institution), leveraging existing domestic consortium registration resources to process LOA tonnage authorization for dibenzyl ether, obtaining official REACH registration numbers printed on SDS, customs documentation and product outer packaging to satisfy German customs import verification requirements;
2. Entrust EU-accredited third-party testing laboratories to issue separate 253-item full SVHC screening reports for the three dibenzyl ether grades, with notarized Chinese-English bilingual test certificates issued alongside updated product substance safety dossiers complying with latest ECHA regulatory requirements;
3. Establish supply chain compliance ledgers, updating REACH information transmission forms alongside each subsequent shipment to fulfill REACH Article 33 supply chain information disclosure obligations.
1. Drawing on latest revised REACH Annex II standards and CLP hazard classification rules, outdated national standard content was removed, supplemented with pharmaceutical workplace exposure parameters, aquatic ecotoxicity data, local German fire & spill emergency response protocols and EP Pharmacopoeia impurity control explanations. Separate complete German native versions and international English versions of SDS were issued and verified with official seals by EU compliance institutions;
2. Simultaneously update product safety labels: 200L iron drum outer packaging uniformly printed with German-English bilingual CLP hazard pictograms, signal words, hazard statements and emergency contact numbers, with full batches rebranded with compliant packaging identifiers.
1. Based on the product’s pharmaceutical-grade fine ether attributes, physical and chemical indicators and end pharmaceutical application, HiSiaddi matched the specialized subdivided pharmaceutical HS code within customs code libraries to correct the original general industrial code misclassification, standardizing declaration elements (purity grade, pharmaceutical application, rectification process);
2. Verify packaging performance certificates and dangerous goods packaging permits per UN1993 Class III dangerous goods specifications, compile full statutory dangerous goods declaration documentation for domestic export, assist manufacturers with on-site customs sampling inspection and obtain official export clearance release certificates to schedule container booking and shipment loading as scheduled.
1. Guide manufacturing plants to conduct full physical, chemical and impurity testing aligned with EP Pharmacopoeia test items, reformat original national standard CoAs into EP Pharmacopoeia-style English CoAs marking EP limit standards and test methods for each impurity item;
2. Assist manufacturers in issuing English GMP production compliance statements and raw material production traceability reports with batch quality control records. The full document set complies with German pharmaceutical enterprise QA warehouse audit standards and can be directly imported into the client’s drug regulatory filing system.
1. Smooth customs clearance & warehouse admission: The full 45-ton dibenzyl ether container passed dual German customs and client QA audits without detention, return shipment or port storage fees, arriving at the client’s production workshop on schedule to resume API manufacturing, avoiding approximately 32,000 Euros in breach of contract losses;
2. Long-term standardized compliance system established: HiSiaddi customized a dedicated dibenzyl ether export compliance archive template for the client, including REACH archives, bilingual SDS templates, EP-format CoA templates and customs declaration templates, eliminating repeated rectification for all monthly split shipments in the annual framework contract;
3. Deepened full-category compliance cooperation: The client designated HiSiaddi as a pre-compliance review service provider for chemical raw material imports into the EU region, with all future benzyl derivative procurement subject to advance compliance pre-audit by HiSiaddi to mitigate import regulatory risks;
4. Cost optimization: Leveraging HiSiaddi consortium registration resources, the client’s subsequent annual REACH registration allocation costs dropped by 62% compared to independent registration, eliminating high service fees for separate European compliance firm engagement.
1. High-end pharmaceutical chemical export success cannot rely solely on compliant product indicators; most domestic manufacturers excel only in production and lack awareness of EU REACH, CLP and country-specific localized regulations. Original supporting documentation is generally tailored for the domestic market and fails multi-layered entry compliance requirements of European and American high-end pharmaceutical enterprises, representing invisible high-risk pitfalls most frequently encountered by overseas high-end clients during procurement;
2. Core Differentiated Value of HiSiaddi: Moving beyond simple product supply logic, HiSiaddi connects domestic commodity inspection, international ocean freight, EU import customs and pharmaceutical enterprise drug regulatory warehouse admission through full-chain compliance capabilities, integrating cross-disciplinary expertise covering chemical regulations, pharmaceutical pharmacopoeia and customs operational practice to resolve multi-dimensional compliance barriers in a one-stop manner;
3. Core Rigorous Demand of European and American High-End Pharmaceutical Enterprises: Controllable compliance carries greater weight than price advantages. Complete traceable compliance documentation aligned with prevailing national and international regulations constitutes a core barrier sustaining long-term high-end client partnerships.
Contact HiSiaddi customer service for more inquiries regarding dibenzyl ether product compliance.
+86-13120989737 
info@hisiaddi.com 
English
